Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canadian Natural Resources Ltd. (CNQ) vs Eli Lilly And Co (LLY) Price & Performance

Canadian Natural Resources Ltd.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Canadian Natural Resources Ltd. vs Eli Lilly And Co — how do they compare? Canadian Natural Resources Ltd. trades at $47.64 (market cap $98.11B), while Eli Lilly And Co trades at $1,220.55 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 11× Canadian Natural Resources Ltd.'s market cap, and Canadian Natural Resources Ltd. pays the higher dividend (3.73%). Which is the better fit depends on your goals.

CNQLLY
Market Cap
$98.11B$1.08T
Sector
EnergyHealth
52-Week High
$50.55$1.24K
52-Week Low
$29.31$639.43
Enterprise Value
$108.54B$1.13T
Dividend Yield
3.73%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canadian Natural Resources Ltd.

Canadian Natural Resources (CNQ) trades at $47.65, up 0.85% with strong technical momentum. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.53 versus $1.43 expected, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 11.82 and EV/EBITDA of 6.35, while profitability metrics impress with 26.69% ROE and 22.87% net margin. Recent news highlights record production and dividend consistency.

CNQ presents a compelling investment case with strong operational performance, attractive valuation, and shareholder returns through dividends. The primary risks include oil price volatility and execution challenges in capital projects. Analyst consensus remains strongly bullish with 27 buy ratings and no sell recommendations, supporting upside potential from current levels.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canadian Natural Resources Ltd.

Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.

Read more on CNQ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY